Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 28, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

September 30, 2030

Conditions
Breast Cancer
Interventions
DIETARY_SUPPLEMENT

Docosahexaenoic acid (DHA)

Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.

DRUG

Placebo oral capsule

Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

University of Alberta

OTHER

lead

AHS Cancer Control Alberta

OTHER

NCT03831178 - Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting | Biotech Hunter | Biotech Hunter